BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 224 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q2 2021. The put-call ratio across all filers is 1.19 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $27,780,000 | -18.9% | 183,768 | -21.8% | 0.06% | +69.7% |
| Q2 2022 | $34,252,000 | +299.9% | 235,068 | +225.4% | 0.03% | +450.0% |
| Q1 2022 | $8,566,000 | -14.0% | 72,243 | +0.0% | 0.01% | -14.3% |
| Q4 2021 | $9,955,000 | -19.8% | 72,233 | -19.2% | 0.01% | -30.0% |
| Q3 2021 | $12,412,000 | +168.6% | 89,350 | +87.7% | 0.01% | +150.0% |
| Q2 2021 | $4,621,000 | +118.6% | 47,602 | +53.9% | 0.00% | +100.0% |
| Q1 2021 | $2,114,000 | +2.9% | 30,939 | +29.1% | 0.00% | 0.0% |
| Q4 2020 | $2,054,000 | +327.0% | 23,962 | +171.7% | 0.00% | – |
| Q4 2019 | $481,000 | -16.9% | 8,820 | -36.5% | 0.00% | -100.0% |
| Q3 2019 | $579,000 | -81.7% | 13,884 | -80.7% | 0.00% | -66.7% |
| Q2 2019 | $3,158,000 | +1.3% | 72,114 | +19.1% | 0.00% | 0.0% |
| Q1 2019 | $3,117,000 | +38.1% | 60,554 | -0.8% | 0.00% | +50.0% |
| Q4 2018 | $2,257,000 | – | 61,023 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 1,111,111 | $107,867,000 | 52.60% |
| Knoll Capital Management, LLC | 856,844 | $83,182,000 | 43.44% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,082,555 | $202,174,000 | 27.86% |
| ARS Investment Partners, LLC | 558,286 | $54,198,000 | 5.52% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $17,113,000 | 4.52% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 401,006 | $38,930,000 | 4.51% |
| Eventide Asset Management | 1,990,797 | $193,267,000 | 2.60% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 56,626 | $5,497,000 | 2.45% |
| Avidity Partners Management LP | 882,500 | $85,673,000 | 2.32% |
| Nicholas Investment Partners, LP | 363,708 | $35,309,000 | 2.22% |